Keymed Biosciences Reports Strong Annual Results and Promising Pipeline Developments for 2024 Keymed Biosciences has announced robust annual results for 2024, showcasing strong sales and significant advancements in their drug pipeline, including Stapokibart.

Keymed Biosciences Reports Strong Annual Results and Promising Pipeline Developments for 2024 #China #Chengdu #Keymed_Biosciences #Stapokibart #CM310